Last reviewed: May 14, 2026
Last updated: May 14, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Semaglutide can be prescribed off-label for weight management in certain patients, though it was originally developed for type 2 diabetes treatment. Clinical trials demonstrate average weight loss of 10-15% of body weight over 68 weeks in participants receiving higher doses.
Weight loss medication selection requires understanding your individual metabolic profile, medical history, and how your body may respond to GLP-1 receptor activation. PlexusDx focuses on precision wellness by evaluating your unique genetic and biomarker context to support informed conversations with your healthcare provider.
How Semaglutide Works for Weight Loss
Semaglutide activates GLP-1 receptors in the brain and gut, increasing satiety signals and reducing appetite. It also slows gastric emptying, helping you feel fuller longer after meals, which may support calorie reduction without conscious dietary restriction.
The medication affects multiple metabolic pathways beyond appetite suppression. Research suggests it influences glucose regulation, lipid metabolism, and may provide cardiovascular benefits in patients with existing heart disease or high cardiovascular risk.
Clinical Evidence and Expected Outcomes
Multiple randomized controlled trials have demonstrated semaglutide's weight loss efficacy. The STEP trials showed participants achieved 10-15% weight loss over 68 weeks, with some reaching 20% loss at higher doses. Results vary significantly based on individual factors including baseline weight, adherence, and diet changes.
| Clinical Trial / Context |
Weight Loss Achieved |
Population Studied |
| STEP 1 (1.0 mg weekly) |
10.2% average at 68 weeks |
Adults with obesity, BMI ≥30 |
| STEP 2 (2.4 mg weekly) |
12.4% average at 68 weeks |
Adults with obesity, no diabetes |
| STEP 3 (2.4 mg weekly) |
13.8% average at 68 weeks |
Adults with obesity + lifestyle intervention |
| STEP 4 (2.4 mg weekly) |
14% average at 68 weeks |
Adults with obesity + intensive lifestyle program |
Medical Eligibility and Who Benefits Most
Semaglutide is prescribed off-label for weight management primarily in adults with BMI ≥30 or BMI ≥27 with weight-related health conditions. Medical criteria include careful screening for contraindications such as personal or family history of thyroid cancer, multiple endocrine neoplasia, or severe gastrointestinal disease.
Optimal candidates typically show commitment to lifestyle changes, realistic weight loss expectations, and no history of pancreatitis or medullary thyroid carcinoma. Your healthcare provider should evaluate your complete medical history, current medications, and metabolic markers before initiating treatment.
Safety Considerations and Provider Guidance
Common side effects include nausea, vomiting, constipation, and diarrhea, often occurring during dose escalation. Most patients experience symptom improvement as their body adjusts, though some may require dose adjustment or medication discontinuation. Severe pancreatitis and gallbladder issues are rare but require immediate medical attention.
Ongoing provider monitoring is essential throughout treatment, including regular blood glucose monitoring for diabetic patients, assessment of gastrointestinal symptoms, and periodic metabolic panel evaluation. Do not start or adjust semaglutide without qualified healthcare provider supervision and informed consent regarding potential risks and benefits.
How PlexusDx Supports a More Personalized Approach
PlexusDx's Precision Peptide Genetic Test evaluates key variants in GLP-1 receptor pathways that may help provide context about individual predispositions to GLP-1 receptor signaling. Variants like GLP1R rs6923761 can support conversations with your provider about whether GLP-1 based medications align with your metabolic profile.
The genetic test also examines GIPR rs1800437 and MC4R rs17782313 variants, which relate to appetite regulation and energy metabolism. These predispositions should be interpreted with your qualified healthcare provider as they indicate genetic factors that may influence medication response, not guaranteed outcomes or exact weight loss predictions.
Having your genetic context informs a more personalized treatment discussion, allowing your provider to weigh semaglutide against other options and adjust dosing or timing based on your individual biology alongside your clinical history and current health status.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is semaglutide FDA-approved specifically for weight loss?
Semaglutide (brand name Wegovy) received FDA approval for chronic weight management at lower doses. Higher-dose diabetes formulations (Ozempic) are often prescribed off-label for weight loss. Your provider determines appropriate use based on your medical profile.
How much weight can I expect to lose with semaglutide?
Clinical trials show average weight loss of 10-15% over 68 weeks, with individual variation. Some patients achieve 20% loss; others lose less. Results depend on genetics, diet adherence, exercise, baseline metabolism, and individual GLP-1 receptor sensitivity.
What does PlexusDx offer for semaglutide consideration?
PlexusDx provides compounded semaglutide from licensed 503A pharmacies starting at $179/month, plus optional Precision Peptide Genetic Testing ($99 add-on or $298 standalone) to evaluate GLP-1 pathway predispositions supporting informed provider conversations.
Can semaglutide cause permanent side effects?
Most semaglutide side effects resolve after discontinuation or dose adjustment. Rare serious effects like pancreatitis require immediate medical attention. Long-term safety data continues to accumulate; ongoing provider monitoring is essential during treatment.
Does the genetic test predict if semaglutide will work for me?
The Precision Peptide Genetic Test reveals predispositions in GLP-1 and appetite-regulation pathways but does not predict exact medication response. Genetics is one factor; clinical history, lifestyle, dose, and adherence significantly influence outcomes. Always discuss results with your provider.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Lose Weight with GLP-1? Exploring the Benefits and Mechanisms of GLP-1 Medications
Understanding the Monthly Cost of Tirzepatide: What You Need to Know